NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Idiopathic Inflammatory MyopathiesDiffuse Cutaneous Systemic SclerosisSLE NephritisANCA Associated Vasculitis

Interventions

DRUG

KYV-101

The KYV-101 will be administered IV as a single infusion dosed at 1×108 CAR+ T cells.

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy of cyclophosphamide (CYC) 300 mg/m2

DRUG

Fludarabine

Lymphodepleting chemotherapy of Fludarabine (FLU) 30 mg/m2 intravenously (IV)

Trial Locations (1)

Hospital of the Universithy of Pennsylvania, Philadelphia